The marked variation that exists in renal replacement therapy (RRT) epidemiology between countries and within countries requires careful systematic examination if the root causes are to be understood. While individual patient-level studies are undoubtedly important, there is a complementary role for more population-level, area-based studies-an aetiological approach. The EVEREST Study adopted such an approach, bringing RRT incidence rates, survival and modality mix together with macroeconomic factors, general population factors and renal service organizational factors for up to 46 countries. This review considers the background to EVEREST, its key results and then the main methodological lessons and their potential application to ongoing work.Keywords: aetiology, epidemiology, macroeconomics, renal replacement therapy, renal service organization
I N T R O D U C T I O N
Aetiology confronts two distinct issues: the determinants of individual cases, and the determinants of incidence rate. If exposure to a necessary agent is homogeneous within a population, then case/control and cohort methods will fail to detect it: they will only identify markers of susceptibility. The corresponding strategies in control are the 'high-risk' approach, which seeks to protect susceptible individuals, and the population approach, which seeks to control the causes of incidence. The two approaches are not usually in competition, but the prior concern should always be to discover and control the causes of incidence [1] .
As clinicians treating patients, we spend most of our time asking why a particular patient got a particular disease at a particular time. While such an individual-centred approach will tell us something about risk factors and susceptibility to disease and guide individual treatment, it will miss large differences in the incidence of diseases between populations and perhaps, therefore, some of the public health lessons that may have the greatest impact [1] . For example, although it had been recognized in the 1950s that bladder cancer rates were higher in northern parts of New England than the rest of the USA, the explanation for this remained elusive. Bringing together area-level bladder cancer mortality rates and data on rates of private water supplies as part of an ecological approach revealed a strong positive association between the two [2] . This led to further work suggesting that the explanation lay in higher levels of contaminants such as inorganic arsenic, manganese and radionuclides in the water obtained from private wells as these sources were not routinely tested [2] . While it is conceivable that this link could have been identified using individual patient studies, the ecological approach (where the units of analysis are populations or groups of people rather than individuals [3] ) provided a very cost-effective way of arriving at this explanation. It is important, therefore, that this approach remains part of the range of research methods that we use. variation in incidence rates of renal replacement therapy (RRT) between countries reporting to the USRDS in 2011 [4] . The extent of variation in the underlying prevalence of chronic kidney disease (CKD) in the general population is becoming clearer, but rates of progression (i.e. the quality of secondary prevention) seem equally important-Norway and the USA have similar prevalence of CKD but very different rates of ESRD, with lower rates of progression proposed as the explanation [5] . A pitfall in studying this relationship is that we do not study incidence rates of ESRD, but those of RRT, and although difficult to study, the gap between the incidence of ESRD and RRT appears still to be present, especially in the elderly [6] . The extent to which this gap reflects patient choice, accuracy of reported causes of death or access to RRT is not known, but with RRT being responsible for ∼1% of total healthcare budgets [7] , the effect of financial pressures on treatment rates must always be considered and monitored.
Until the 1990s, international differences in RRT incidence rates and outcomes were generally attributed to rationing of dialysis in some countries [8] and the inability to adjust for case-mix with existing registry data [9] . In the USA, this led to the Dialysis and Outcomes Practice Patterns Study (DOPPS) [10] , which became an international collaboration. While brilliantly utilizing instrumental variable analysis in an attempt to determine causality from observational data, the DOPPS was not designed to deal with differences in the incidence of RRT or the factors influencing patient transitions between various modalities of RRT and the effect that these have on inter-centre or international comparisons.
The EU took a very different approach. It funded a retrospective cohort study of incident dialysis patients in five countries, which confirmed a 60% lower case-mix-adjusted mortality on dialysis in centres in France and Germany compared with Scotland [11] . This led to the prospective European Dialysis and Cost-effectiveness (EURODICE) Study [12, 13] , which sought to overcome issues of ascertainment bias and unmeasured confounding while also capturing information about resources available for dialysis-something that the authors had become convinced were impacting on outcomes in the original study [11] . Unfortunately, it turned out not to be possible to bring together the detailed case-mix and quality-of-life-adjusted EURODICE data with national registry data in one Markov modelling exercise.
A first shift towards recognizing and trying to capture the influence of the health of the general population and the organization of the renal service came from a collaboration between the UK and German renal registries [14] . These two northern European countries were, on the surface, very similar, yet had very different RRT incidence rates. This descriptive paper concluded that much of the 80% higher RRT incidence rate in Germany was likely due to higher rates of diabetes, hypertension and ischaemic heart disease and perhaps a lower cardiovascular mortality rate (and therefore lower chance of dying before reaching ESRD) in the general population, particularly in the elderly, although marked differences in resources and access to treatment were also noted [14] .
E V E R E S T : T H E A P P ROAC H A N D M A I N F I N D I N G S
So it was on the back of these studies that the EVEREST Study -Explaining the Variation in Epidemiology of RRT through Expert opinion, Secondary data sources and Trends over time Study-was developed [15] . EVEREST focused on (i) the incidence of RRT, (ii) the use of peritoneal dialysis (PD) and (iii) the survival of incident patients on dialysis, all measured at a national level by national renal registries. As these do not routinely collect data on the organization of renal services, national experts, usually approved by national societies, were surveyed to capture potential determinants of incidence rate, dialysis modality mix and patient survival. In addition, existing, validated sources such as the World Health Organization (WHO) and the Organisation for Economic Development (OECD) provided the population health metrics, supplemented with national data where needed [15] .
Of the 51 potentially eligible national renal registries across the globe, 46 collaborated fully both with renal registry and national expert data. Among these countries, RRT incidence ranged from 12 to 455 per million population (inter-quartile range 102-167). With these data, it was possible to show, for the first time, an independent positive association between RRT incidence and national wealth [a 2% higher RRT incidence for each additional 1000 US Dollars of gross domestic product (GDP) per capita] and the percentage of national wealth spent on healthcare (an 11% higher RRT incidence for each additional 1% of GDP spent on healthcare); an independent negative association was, however, observed between facility reimbursement rate adjusted for national wealth and RRT incidence (a 24% lower RRT incidence for each doubling of the reimbursement rate) [16] . In more developed countries, there was also an independent positive association between the private for-profit share of haemodialysis (HD) facilities and the incidence of RRT (a 1% higher RRT incidence for each additional 1% of HD facilities in the private for-profit sector), although in this case, the cause and consequence in the relationship could obviously not be determined. It is noteworthy that none of the RRT or general population demographics proved independently associated with RRT incidence.
Two-year unadjusted survival on dialysis also ranged considerably between countries, from 62% in Iceland to 90% in Romania [17] . Macroeconomics also appeared to dominate here, although the background mortality rate of the general population was also a determinant in this analysis. Counter-intuitively perhaps, greater national wealth and a greater percentage of national wealth spent on healthcare were associated with higher mortality on dialysis-a 2% higher mortality was observed for each additional 1000 US Dollar of GDP per capita and a 10% higher mortality was observed for each additional 1% of GDP spent on healthcare [17] . To explore this relationship as far as possible within the existing data, two possible pathways were proposed and presented in a theoretical framework ( Figure 1 ): (i) An incidence of dialysis pathway-as neither RRT incidence nor the percentage of the dialysis population with diabetes (i.e. characteristics of the incident dialysis population) were associated with survival on dialysis, it was concluded that macroeconomics were unlikely to be acting through the incidence of dialysis.
(ii) A quality of dialysis care pathway-although none of the measured renal service organizational factors were significantly associated with survival on dialysis, data were not uniformly available for quality of care indicators to allow examination of the (still counter-intuitive) possibility that the greater the share of national wealth spent on healthcare the lower the quality of care on dialysis and as a result the lower the survival [17] .
By setting out these possible pathways between the determinants and outcome variables, the theoretical framework underpinned the models that were created to explore these associations as far as possible using the existing data.
The percentage of patients on PD by Day 91 ranged from 0% in Luxembourg to 49% in New Zealand, with macroeconomic, renal service and health status indicators all proving independently associated with this outcome [24] . PD was less common as the percentage of national wealth spent on healthcare increased (a 7% lower use of PD for each additional 1% of GDP spent on healthcare), the share of HD centres run by the for-profit sector increased (a 0.4% lower use of PD for each additional 1% of HD facilities in the private for-profit sector) and the cost of PD consumables (relative to staffing) increased (a 3% lower use of PD for each 10% higher cost of PD consumables relative to staffing). Having a higher percentage of patients with diabetes was associated with a lower use of PD (a 7% lower use of PD for each 5% higher percentage of incident patients with diabetic kidney disease) [24] .
Again, in order to better understand how macroeconomic factors might influence the use of PD, a theoretical framework was developed and the pathways were explored (Figure 2 ): (i) The incidence of dialysis pathway-macroeconomic factors had already been shown to be positively associated with RRT incidence and therefore it might be expected that the incident RRT population would be older and frailer and less suitable for home dialysis. Analyses had also shown that the higher the percentage of incident RRT patients with diabetes (a surrogate indicator of co-morbidity) the lower the use of PD in a country, a finding that would support macroeconomics working through this pathway.
(ii) The regulatory constraint pathway-limited funds for investment in capital-intensive healthcare technologies like HD was hypothesized to potentially put pressure on renal services to expand home dialysis programmes (including PD). Unfortunately, the national expert data in the EVEREST study were not sufficiently robust to formally test this pathway.
The interpretation of these results has been outlined in the relevant papers [16, 17, 24] and so the purpose of the second part of this review is to reflect on the lessons from conducting EVEREST and its implications for future research.
E V E R E S T : M E T H O D O LO G I CA L L E S S O N S L E A R N E D
Reliably identifying potential determinants and capturing them at the necessary level A major challenge for EVEREST was the capturing of the renal service variables. A systematic approach was taken to identifying anything organizational that had been proposed in the literature to be associated with RRT incidence. Experts from around the world were then consulted for their ideas on factors relevant in their countries that may not appear in the [17] , with permission.) Considering the incidence of dialysis pathway, macroeconomic indicators may be associated with the health status of the general population in a country as well as its renal service organization. Both macroeconomic factors and the health status of the general population have been shown to be associated with the incidence of RRT [16] . Moreover, they are likely to be associated with the characteristics of the incident dialysis population, because a higher incidence frequently goes hand in hand with the inclusion of more high-risk patients [18, 19] . The latter has shown to be related to mortality on dialysis [9, 20, 21] . Considering the quality of dialysis care pathway, we hypothesized that macroeconomic indicators and the organization of renal services may directly be linked with the quality of dialysis care, something that has previously been known to be related to mortality on dialysis [21] [22] [23] .
literature. Some of the factors that were identified during the subsequent interviews, however, were very country-specific and not considered when the survey was being prepared. In future studies, we would recommend surveying a wider range of national opinions when trying to identify the potential determinants for the survey and formalizing that process within modified Delphi/consensus methods to give those contributors an equal say [25] . A more rigorous piloting of the national expert survey might also be undertaken using cognitive interviewing methods to refine the questions, develop definitions where necessary and minimize ambiguity [26] . Finally, the optimum number of observations for a particular country should be established. For some renal service characteristics, generally those that are objective such as number of nephrologists, a single (or small number of ) evidence-based response(s) is all that is required, although even the definition of 'a nephrologist' needs to be carefully considered and may depend on the patient group being studied! For other more subjective/qualitative responses, however, a much greater number of responses will be required. Determining the optimal number is difficult, but we can perhaps be guided by some work done by the WHO in developing their Responsiveness Index for healthcare systems [27] . The Responsiveness Index attempts to capture the quality of healthcare that is not related to hard health outcomes, broadly summarized as 'Respect for persons' and 'Client orientation', in a diverse range of countries around the world. For this, they utilized their existing network of focal persons in regional offices who identified the 50 key informants who represented the whole of the country [28] . Although this number may seem quite high for nephrology studies, future studies should establish the optimum sampling frame and size for surveying clinicians and managers in order to be able to reliably capture the heterogeneity of renal service characteristics within a country.
Including within-country heterogeneity in the models Another limitation of the study was that observations were made at a national level and therefore all the potential heterogeneity at the (sometimes autonomous) regional healthcare level could not be studied. For example, while the prevalence of diabetes mellitus varies worldwide [29] , it also varies within countries [30] with emerging evidence that the quality of care patients receive also varies [31] . The difficulty is obtaining similar detailed population health data at anything other than a national level for more than one or two countries. Similar issues arise with the macroeconomic data, which have also been show to vary markedly within countries [32] .
Part of the solution to the within-country heterogeneity problem is multi-level modelling, and indeed this lesson was applied to work looking at regional variation in RRT incidence [33] and use of home dialysis [34] in the UK. Data were collected at various levels depending on the outcome being considered-the individual patient, the local health area and the area covered by the renal unit-thus allowing the effect of various characteristics to be studied at these different levels. In France, Couchoud et al. [35] adopted a similar approach to look at the relative contribution of individual characteristics and centre practices. Extending these multi-level approaches to a larger number of countries with renal services at similar stages of development seems likely to be the way forward. This will also overcome some of the limitations in quality and granularity of renal registry data and allow greater flexibility in the analyses that could be done in subgroups of countries with individual-level data and those with aggregate-level data.
The decision to adopt a national approach had been very carefully considered, however, and was based on concerns about clustering of outcomes and characteristics within countries and the lack of availability of much of the macroeconomic, population health and renal service data at a regional level. One advantage of this approach was that observations for the outcomes and determinants were based on countries-the variability that must be taken into account was therefore much smaller and the point estimates of coefficients much more precise than would be expected for an individual patient-level study of the same sample size.
A P P LY I N G T H E S E L E S S O N S TO O N G O I N G S T U D I E S
Lessons from EVEREST are relevant to a number of ongoing studies in Europe and further afield. At the ERA-EDTA F I G U R E 2 : Theoretical framework of the different indicator groups and their hypothesized relation with modality mix through two different pathways. (Reproduced from van de Luijtgaarden et al. [24] , with permission.) Determinants included in the models: (1) GDP per capita, health expenditure as % GDP, public share of healthcare expenditure; (2) the private for-profit share of HD facilities, number of dialysis centres per million population, cost of PD consumables relative to staffing, reimbursement rate for HD relative to PD; (3) percentage of dialysis population aged 65+ years, percentage diabetes as primary renal disease.
Registry, a doctoral fellowship is examining the prevalence and progression of CKD in published and unpublished studies in Europe and aims to collect survey data on resources and healthcare system characteristics with a view to exploring the independent associations between these and CKD rates (Dr K. Brück, personal communication). This provides an opportunity to develop and refine the sampling methods needed to obtain robust data that capture the heterogeneity in resources and organization that exists at various levels within countries. At the same time, the International Society of Nephrology has funded the Kidney Health for Life (KH4L) International Collaboration to undertake a comprehensive inventory of CKD care with the goal of identifying the present status, gaps and inequalities in care for CKD patients and provide recommendations to improve the standard of that care. KH4L intends to use a different approach-desk research and in-person interviews (1:1 or focus groups)-although the importance of capturing regional differences in some countries has been flagged as needing particular attention [36] .
There is also interest in the role of macroeconomics and service organization in paediatric nephrology. In 2011, the European Society of Paediatric Nephrology (ESPN)/ERA-EDTA Registry surveyed registry representatives in 38 countries to establish policies and practices relating to paediatric kidney transplantation with a view to establishing how much of the disparities in transplant rates are explained by variation in practices and nonmedical factors such as national wealth [37] . More recently, the ESPN/ERA-EDTA Registry has obtained funding from the Executive Agency for Health and Consumers, an institution of the European Commission, to study health inequalities in RRT with particular focus on policies and practice patterns [38] .
More difficult is establishing cause and effect from such observational, ecological studies. It is obviously not possible to improve outcomes for kidney patients by altering macroeconomics, but it is still important to understand the relationship between economics and health outcomes, for example, monitoring the impact of major changes in national wealth and spending on healthcare on access to and outcomes on RRT. Such changes impacted majorly on the health of eastern European populations in the 1990s following the dissolution of the Soviet Union [39] with reduced access to healthcare and widening health inequalities [40] . More contemporaneously, the economic downturn that began in 2008 has already been shown to have been associated with increases in suicides, outbreaks of infectious diseases and restricted access to healthcare [41] , with closure of outpatient facilities, closure of hospital beds, reductions in staff numbers and increased co-payments for patients [42] . Given the cost of RRT and increasing age and vulnerability of patients developing ESRD, the need for renal registries to continuously monitor RRT incidence rates, prevalence and survival has never been greater.
The EVEREST Study has demonstrated, for the first time, the independent nature of associations between macroeconomics, population health and renal service organization and dialysis treatment rates and outcomes. While these results are unlikely to ever lead to studies manipulating macroeconomics to improve outcomes for dialysis patients, they highlight the importance of monitoring the treatment rates and outcomes of the life-saving but relatively high cost treatments we provide in times of financial austerity. Further, systematic approaches to understanding possible pathways behind the associations observed may lead to the identification of the key intermediaries working at a population level which may themselves be modifiable and testable in future studies.
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